Condition: Age-Related Macular Degeneration · Sponsor: Chengdu Origen Biotechnology Co., Ltd.
KH631 is a adeno-associated virus (AAV) vector-based gene therapy for subretinal injection. The long-term, stable therapeutic protein after one time injection for nAMD could potentially reduce the treatment burden and maintain vision.
This description comes directly from the study's public registry record.
Qiang Zheng · 86 13880331037 · zhengqiang@cnkh.com
Shanshan Ji · 86 18188058101 · 022078@cnkh.com
Always discuss trial participation with your own doctor first.
| Beijing Tongren Hospital, Capital Medical University | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05672121